The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Michal Bar-Natan, Weill Cornell Medicine, New York, US, shared her highlights with the AML Hub.
What were your highlights from ASH 2023?
Bar-Natan discusses recent data on menin inhibitors for the treatment of relapsed/refractory KMT2A-rearranged or NPM1-mutated acute myeloid leukemia. This includes trials assessing JNJ-75276617 monotherapy, revumenib monotherapy (AUGMENT-101 trial), revumenib in combination with decitabine and cedazuridine plus venetoclax, and ziftomenib in combination with either intensive chemotherapy or non-intensive chemotherapy in both relapsed/refractory and first-line settings.
This interview is also available as a podcast here.
